Quisinostat

Drug Profile

Quisinostat

Alternative Names: JNJ-26481585

Latest Information Update: 23 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Pharmaceutica; Janssen Research & Development; NewVac
  • Class Antineoplastics; Hydroxy acids; Hydroxylamines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lung cancer; Ovarian cancer
  • Phase I Breast cancer; Sarcoma
  • Discontinued Cutaneous T cell lymphoma; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 05 Jul 2017 Discontinued - Phase-I for Multiple myeloma (Combination therapy) in France (PO) (NewVac and Janssen pipelines, July 2017)
  • 05 Jul 2017 Quisinostat is still in phase II development for Ovarian cancer (NewVac and Janssen pipelines, July 2017)
  • 26 Jun 2017 Efficacy and safety data from a phase II trial in Ovarian cancer presented at the American Society of Clinical Oncology Annual Meeting (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top